I agree, with the request it points tlmore toward acceptance rather than rejection. Also the funding is favorable to investors so the news this year has been positive.
Exactly, RMAT is designed to allow companies to work with the FDA on new and innovative regenerative medicine. It allows the FDA to monitor this new sector, without inhibiting medical progression.
The new head of the FDA wants this to succeed. He's a big supporter of this movement.
It appears that us stem cell is working WITH the FDA to get this ball rolling. It may take time as this is a NEW program for the FDA. But the transparency here is a great sign for the future. Good thing coming
News 
Market Data 
Discover 
AI
